BELGIUM-WALLONIA

@ BIO-EUROPE SPRING 2024

Booth # 07

2024, March 18 - 20 | Barcelona – CCIB

Wallonia.be



Wallonia has an excellent logistics infrastructure and «multimodality» is the keyword. **Liege Airport** was awarded the title of **best cargo airport in the world** for the year 2020.

You will also find yourself well supported: the actors of the **Life sciences** sector are gathered in the **BIOWIN health cluster**.

Wallonia.be

WALLONIA EXPORT & INVESTMENT AGENCY

The Wallonia Export & Investment Agency (AWEX) is the institution in charge of the development and management of Wallonia's domestic and international economic relations.

Through a personalized, innovative, and sustainable approach, AWEX supports Walloon companies - regardless of their size, sector, or target market - in every step of their international endeavors. This includes exports, technological partnerships, and development abroad.

The agency's vast network of connections ensures the best advisors are always by your side. Our local anchors and agents abroad are capable of providing unparalleled insight to take your company to the next level. In addition, our connections will help establish your business in the global marketplace and promote it throughout the world. Training, incentives, and international financing are also available.

AWEX is also committed to strengthening Wallonia's position as the premier gateway for international investors seeking success in the heart of Europe. We work closely with them to inform, convince, and advise in every stage of their development.

Feel free to get in touch with one of our local or international agents via our websites listed above.

In our network of more than 400 employees in nearly 100 countries around the world, there is always someone ready and willing to support you in your approach.

Place Sainctelette 2
B - 1080 Brussels
info@awex.be

www.awex.be/en
www.investinwallonia.be
www.wallonia.be

Wallonia Export | Facebook
www.linkedin.com/company/
wallonia-export-investment-agency/

Ms Pascale DELCOMMINETTE, CEO

Wallonia.be
EXPORT
INVESTMENT

BIOWIN

About BioWin

BioWin is the health cluster in Wallonia, Belgium, the regional reference for all stakeholders in biotech, e-health and medtech research and innovation projects. It includes 250 members from the private, public and academic sectors.

Its mission is to accelerate innovation to meet tomorrow's public health challenges and develop the knowledge, employment and competitiveness of the life sciences ecosystem in Wallonia.

Founded in 2006, BioWin brings together all the innovation system players in the field of health (biopharma and medtech) in Wallonia, with the goal of stimulating regional economic redeployment. The cluster is also involved in implementing the sector's industrial policy (industrial innovation and research, training, and support for business growth).

Business Village Ecolys
Avenue d'Ecolys 2
5020 Namur (Belgium)

CONTACT
Mr. Damien Diop,
Head of Membership Development
+32 472 19 80 91
damien.diop@biowin.org
www.biowin.org

BIOWIN

In attendance in Bio-Europe Spring

- **Belgium – Wallonia Export & Investment Agency**

Brussels Head office

Ms Marie Anne Dantinne, Project Manager| Fairs & Events
+32 495 30 73 22
m.dantinne@awex.be

Mr Mehdy Oozeer, Senior Life Sciences Specialist
+32 498 56 22 15
m.oozeer@awex.be

www.investinwallonia.be
www.awex.be/en

Spain – Barcelona office

Mr Gilles Philippart de Foy, Trade and Investment Counsellor
+34 93 487 77 26
+34 619 302 704
g.philippartdefoy@awex-wallonia.com
www.awex.es

- **Biowin**

Ms Alexandra Schiettekatte, Head of Communications
+32 476 65 04 38
www.biowin.org

EXHIBITORS

AMYL THERAPEUTICS

Legia Park, Boulevard Patience et Beaujonc, 3, Bte 12
B - 4000 Liège
www.amyltx.com

CONTACT
Dr Pierre Vandepapelière, CEO
+32 472 96 00 17
p.vandepapeliere@amyltx.com

COMPANY BACKGROUND
Amyl therapeutics is developing a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases, ie amyloidosis and neurodegenerative diseases. Very experienced pharma and biotech team, combining internal and outsourced development. Given the recent validation of anti-beta-amyloid monoclonals by Lilly and Biogen, Amyl candidates that are specific to multiple amyloid fibrils target (beta-amyloid and Tau and alpha synuclein targeting fusion protein). In addition, the mode of action involves prevention of fibrils aggregation and cleaning of fibrils deposits, will build next-generation therapies of amyloid mediated diseases. Demonstrated value and Mode of Action of the platform in AL amyloidosis, endorsed by the German and Belgian regulatory. Moving to GMP process for clinical development.

ADDED VALUE
Several potential indications: rare, severe diseases (amyloidosis) and neurodegenerative disorders.
Differentiated and validated, broad and specific mode of action. Strong non-clinical POC in AL amyloidosis, heading to clinical. Solid non-clinical data in neurodegenerative disorders, being consolidated.
Little investment for major stake, thanks to premoney and impressive non-dilutive support. Very experienced management.

RANGE OF PRODUCTS
Amyl Candidate selected for LC amyloidosis, in GMP process development.
Amyl candidates in evaluation for various neurodegenerative disorders.

MAIN REFERENCES
https://www.lecho.be/entreprises/pharma-biotechnologie/amyl-therapeutics-une-nouvelle-approche-contre-les-maladies-neurodegeneratives/10504461.html.

CERTIFICATIONS
Amyl Therapeutics is accredited as a SME in EU.

BELGIUM-WALLONIA@BIO-EUROPE SPRING 2024

BELGIAN VOLITION

Rue Phocas Lejeune, 22
B - 5032 Les Isnes
info@volition.com
www.volition.com

CONTACT
Mr Emmanuel Demillecamps, Head of Business Development
+32 470 10 54 58
e.demillecamps@volition.com

COMPANY BACKGROUND
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com. Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

RANGE OF PRODUCTS
Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. Volition's research and development activities are centered in Belgium, with an innovation laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

CERTIFICATIONS
CE-IVD, ISO.

BRIDGE2HEALTH

Rue Lambert Lombard, 3
B – 4000 Liège
contact@b2h.be
www.b2h.be
www.linkedin.com/company/bridge-2-health

CONTACT
Ms Lucie Gobert, Project Manager
+32 489 20 66 86
l.gobert@eklo.be

COMPANY BACKGROUND

Bridge 2 Health emerged from the passion, commitment, and robust collaboration of three key players in Liège's life sciences ecosystem: the University of Liège, the University Hospital of Liège, and the Noshaq investment fund, with the active participation of the Walloon Region.

ADDED VALUE

Bridge 2 Health serves as your gateway to Liège's life sciences ecosystem.
We offer tailored services for organizations ranging from small laboratories to global companies, addressing specific needs at every stage of development.
We are seamlessly plugged into the beating heart of financing, working closely with Noshaq and Wallonie Entreprendre (WE), regional investors headquartered in Liège, which also interacts with several national and European funds. No matter where you stand in your journey, we have bespoke funds crafted for your ambitions and the connections to elevate your financial strategy.

RANGE OF PRODUCTS

Are you a life sciences small or medium-sized enterprise (SME)? Are you a start-up or spinoff seeking expansion and connections within the existing life sciences community? Is your foreign life sciences company considering establishing a presence in Liège?
Our missions? Promote, connect, and develop. We promote and represent the interests of our ecosystem at national and international levels. We connect you to the valuable resources and skills necessary to unlock your organization's full potential. We develop relationships and build bridges between key actors and stakeholders.

MAIN REFERENCES

Samabriva, Hillgene, ABSCINT, EXO Biologics, etc.

BELGIUM-WALLONIA@BIO-EUROPE SPRING 2024

CELYAD ONCOLOGY

Rue André Dumont, 9
B - 435 Mont-Saint-Guibert
info@celyad.com
www.celyad.com
www.linkedin.com/company/celyadoncology

CONTACT
Mr David Georges, VP Finance and Administration
+32 478 44 02 36
dgeorges@celyad.com

COMPANY BACKGROUND

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor (CAR) T-cell therapies for cancer. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies.

CONVEYXO

Brussels South Charleroi BioPark
Rue Auguste Piccard 48
B - 6041 Gosselies
info@conveyxo.com
www.conveyxo.com
www.linkedin.com/company/conveyxo/

CONTACT
Mr Frédéric Tonglet, Deputy CEO
+32 496 38 09 64
frederic.tonglet@conveyxo.com

COMPANY BACKGROUND

convEyXO is a Belgian BioTech/MedTech company founded in 2019 active in the field of therapeutic exosome. We develop a therapeutic portfolio in fibrosis and chronic inflammatory disorders area. We accelerate our go-to-clinical with our scalable process to produce high concentration of purified exosomes and we leverage biomaterial transfer properties of exosomes with payloads of choice using a microfluidics channeled based technology.

ADDED VALUE

In the area of fibrosis and chronic inflammatory disorders area, osteoarthritis (OA) has been chosen as our first proof-of-concept. 4 other fields are in (co-)development at the moment. We developed a BioTechnology Platform enabling us to overcome main challenges of therapeutic exosomes which brings 2 solutions:
A) robust and scalable process to produce high concentration of purified exosomes in a cost-efficient way. Results substantially overcome yield obtained with current fixed bed from equipment players
B) a microfluidics channeled based technology to load exosomes postproduction with drug substances (miRNA, SiRNA, protein, ...) without altering the exosomes to enable the development of innovative treatments.

RANGE OF PRODUCTS

• Therapeutic portfolio.
• Manufacturing: The convEyXO platform is based on optimizing growth conditions directly in multiple 3D mini fixed-bed bioreactors in parallel. By using this technology, we can achieve optimized results rapidly and at a fraction of the cost. Once the process has been validated, the transition to larger 3D environment is considerably de-risked. We have a 10 fold higher concentration of purified exosomes compared to using fixed-bed bioreactor from market players. We have demonstrated the scalability of our technology and consistency of the yield.
• Loading: exosomes enrichment by loading them with a drug substance of interest. ConvEyXO's technology is based on the micro-fluidics' principles, which allows exosomes to circulate in nano-channels with the drug substance. Loading efficiency is up to higher to current standards, exosomes are not altered and the technology is applicable to miRNAs.

EXO BIOLOGICS

Boulevard de Patience et Beaujonc, 3/2
B - 4000 Liège
info@exobio.be
wwww.exobio.be
www.linkedin.com/company/exo-biologics

CONTACT
Mr Romain de Rauville, CBO
+32 493 78 95 96
r.derauville@exobio.be

COMPANY BACKGROUND

EXO Biologics is a clinical-stage Belgian biotechnology company specializing in the development of biopharmaceuticals using exosomes to treat unmet medical needs. Partnering with leading academic researchers, EXO Biologics is ideally placed to set the stage for future nanomedicines. The Company's development strategy focuses on novel drug candidates for therapeutic applications in respiratory diseases, inflammatory bowel diseases, neurology, and oncology. EXO Biologics' lead candidate EXOB-001 is studied in a Phase 1/2 clinical trial targeting Bronchopulmonary Dysplasia (BPD) in preterm newborns. EXO Biologics is the first company in the world to enter clinical phase I/II in EU with MSC based exosomes.

ADDED VALUE

• EXOB-001, first MSC based exosome product to enter clinical trial in EU.
EXO Biologics has developed EXOB-001, a novel exosome-based drug candidate produced with the proprietary manufacturing platform ExoPulseTM. Exosomes are derived from cultured human umbilical cord mesenchymal stromal cells (hMSCs). In 2023, EMA authorized Exo Biologics to start multi-centre adaptive, seamless Phase 1/2 trial with EXOB-001. The trial is assessing the safety and efficacy of intratracheal administration of EXOB-001 in preventing severe forms of Bronchopulmonary Dysplasia (BPD) in preterm newborns.
• ExoXpert, first exosome specialized CDMO with a manufacturing platform used in clinical trial.
Based on its leadership in manufacturing, characterizing and regulatory track record, Exo Biologics has created ExoXpertTM in 2024. ExoXpert is an exosome specialized CDMO providing development and manufacturing capabilities to exosome product developers. Located in Belgium, ExoXpert provide the manufacturing platform ExoPulse to help exosome drug developer accelerate their product development and start clinical trial faster.

CERTIFICATIONS

EXO Biologics has been granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA and ODD by EMA for EXOB-001 for the prevention of Bronchopulmonary Dysplasia (BPD) in preterm newborns. EXO Biologics has received EMA approval to start EVENEW clinical phase I/II with MSC based exosomes.

EYED PHARMA

Rue Louis Plescia, 9
B - 4102 Seraing
info@eyedpharma.com
www.eyedpharma.com
www.facebook.com/search/top?q=eyed%20pharma
(1) «eyed pharma» | Search | LinkedIn

CONTACT
Ms Romy Rizzo, Business Development Manager
+32 498 12 40 67
r.rizzo@eyedpharma.com

COMPANY BACKGROUND

Eyed Pharma is a clinical stage pharmaceutical company aiming to enhance patients' vision globally and to become a leader player in micro-implants releasing drug for various Ophthalmological conditions. Our strong technological expertise and IP is materialized in three different technological platforms of micro-implants and a highly proprietary GMP approved manufacturing process. Our micro-implants ensure a local delivery with a controlled release of well-known molecules for durations that can go up to 9 years.

ADDED VALUE

Our micro implants, allowing an "on target treatment" helps to ensure a 100% patients' compliance and to drastically reduce (eliminate) side effects that form the common unmet needs of eye drops therapies and other systemic modes of administration of ophthalmic therapeutic molecules. This technology may address many more therapeutic applications beyond ophthalmology. For example, we are currently considering the development of products to address unmet needs in ENT or oncology.

RANGE OF PRODUCTS

The first indications targeted by our portfolio of micro-implants under development are Glaucoma, Dry Eye, and DME. Our most advanced innovative micro-implant candidate, TimoD®, designed to ensure Glaucoma management for min 3 years is currently in PhI, interim results are expected end H1 2024. Our Dry Eye & DME products are short to market opportunities.

CERTIFICATIONS

EyeD is ISO13485:2016. Our manufacturing plant is GMP approved & FDA approvable.

IDDI

Avenue Provinciale, 30
B – 1340 Ottignies - LLN
info@iddi.com
www.IDDI.com
IDDI - International Drug Development Institute | Ottignies-Louvain-la-Neuve | Facebook
www.linkedin.com/company/iddi
twitter.com/IDDI_Official

CONTACT
Mr Erik Falvey – Sr Director Business Development EU
+33 6 85 86 44 55
erik.falvey@iddi.com

COMPANY BACKGROUND

IDDI is an expert clinical data services & high-level strategic consulting CRO, providing biometrics services for pharmaceutical, biotechnology, and medical device/diagnostic companies. IDDI also supports investor firms during their due diligence process offering a statistical evaluation of the medicines they are to invest into or rescuing failed clinical trials.

ADDED VALUE

IDDI offers a distinctive blend of methodological precision, scientific proficiency, and operational effectiveness accelerating your trials, making them more streamlined, while ensuring clinical data is prepared for submission. We combine the medical expertise, biostatistical acumen and profound knowledge of the regulatory environment that are required to design and launch clinical trials.

RANGE OF PRODUCTS

- Clinical STUDY DESIGN .
- Advanced BIOSTATISTICS: SAP, statistical analyses, meta-analysis, statistical inputs to publication, IDMCs.
- End-to-end CLINICAL DATA MANAGEMENT: eCRF design, set-up & validation, data import & reconciliation, medical coding, data export and pooling of databases.
- INTEGRATED EDC-RTSM: Randomization &Trial supply management, Electronic Data capture & medical coding.
- REGULATORY Consultancy.

CERTIFICATIONS

CDISC registered provider – Medidata Rave EDC Accreditation.

KIOMED PHARMA

Rue Haute Claire, 4
B – 4040 Herstal
contact@kiomedpharma.com
www.kiomedpharma.com
www.linkedin.com/company/kiomed-pharma

CONTACT
Mr Houtaï Choumane, CEO
+32 476 92 24 47
houtai.choumane@kiomedpharma.com

COMPANY BACKGROUND

KiOmed Pharma develops a unique pipeline of medical devices that address unmet medical needs in high-impact pathologies and major social burdens such as invalidating OsteoArthritis, Skin Aging and Ophthalmology.
KiOmed Pharma's innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative.

ADDED VALUE

The patented technology KiOmedine® CM-Chitosan offers competitive advantages thanks to its immune-compatibility and unique structure. Our scientific team has conducted a large number of safety and efficacy studies to demonstrate the unrivaled properties of our technology in various applications:
• Outstanding capacity for scavenging of reactive oxygen species (ROS).
• High ability to protect tissues against oxidative stress.
• Excellent lubrication properties.

RANGE OF PRODUCTS

KioMedineVsone is a unique injectable fluid implant CE-marked for OsteoArthritis treatment. The product was launched in 2022 in several EU and ME markets to an excellent reception from physicians and patients. A single shot of KioMedineVsone significantly reduces knee pain for more than 6 months with a response rate up to 76%.

CERTIFICATIONS

KiOmed Pharma complies with the Medical Device Directive (MDD) 93/42/EEC, applicable parts of the Medical Device Regulation (MDR) EU 2017/745 amended by the Regulation EU 2020/561, the ISO 13485:2016 International Standard, and the Good Distribution Practice of medicinal products.

MITHRA PHARMACEUTICALS

Rue Saint-Georges, 5
B - 4000 Liège
info@mithra.com
www.mithra.com
www.facebook.com/mithrapharmaceuticals
www.linkedin.com/company/1456363/
www.twitter.com/mithrapharma

CONTACT
Mr Quentin Groutars, Business Development Manager
qgroutars@mithra.com

Mr Jean-Manuel Fontaine – Chief Business Officer
jmfontaine@mithra.com

COMPANY BACKGROUND

Transforming women's health through innovation.
Mithra is a Belgian biotech company created in 1999 dedicated to transforming Women's Health by offering new choices through innovation based on a unique molecule called Estetrol (E4), a native estrogen that offers a differentiated benefit/risk profile compared to existing hormone-based solutions.
Thanks to the commitment of its employees based on two sites, among which a majority of women, Mithra stands by its goals to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.
Mithra relies on two complementary innovative platforms: an Estetrol-based portfolio and Complex Therapeutics which are complemented by a unique manufacturing facility, Mithra CDMO and leveraged by Mithra's know-how in long-acting drug development using polymer technology.

ADDED VALUE

Biotechnology / R&D Services.

RANGE OF PRODUCTS

Contraception, Menopause, Wound healing, Neuroprotection, Breast/Prostate Cancer, Drug development and manufacturing.

MAIN REFERENCES

ESTELLE®, DONESTA® and MYRING® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

CERTIFICATIONS

GMP -GDP.

OP2LYSIS DEVELOPMENT

Boulevard Patience et Beaujonc, 3
B - 4000 Liège
www.op2Lysis.com
www.linkedin.com/company/15190078

CONTACT
Mr Christophe Gaudin, CEO
+33 6 07 97 90 08
christophe.gaudin@op2lysis.com

COMPANY BACKGROUND

Op2Lysis is a French-Belgian biotech company focused on the development of innovative new treatments for patients with cerebrovascular thrombotic diseases, entering clinical phase within less than 18 months. Looking to complete their €27-33 M EUR Series A round. Op2Lysis is led by an experienced team combining biopharma, technology, cardiovascular/neuroscience, clinical and project management and business expertise, and backed by a robust BoD and renown SAB.

ADDED VALUE

The proceeds will be used to:
• complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with supra-tentorial hemorrhagic stroke (see: Brain. 2023 Nov 2;146(11): 4690-4701.doi: 10.1093/brain/awad237) Orphan Drug Designations already granted by the FDA and the EMA.
• develop their pipeline of thrombolytic agents, based on their unique NANOp2Lysis® platform, for indications such as infra-tentorial hemorrhagic stroke and ischemic stroke.

MAIN REFERENCES

Op2Lysis team has demonstrated capacity to raise equity capital (€2.8M) and to secure non-dilutive funds from European Innovation Council accelerator, bpifrance and Wallonia. De-risked developments.

CERTIFICATIONS

Potential for accelerated/conditional approval as soon as 2028, market exclusivity and favorable pricings in a favorable competitive landscape (unmet medical need life-threatening condition/no approved treatment yet).

BELGIUM-WALLONIA@BIO-EUROPE SPRING 2024

PDC LINE PHARMA

Boulevard Patience et Beaujonc, 3 Bte 6
B – 4000 Liège
contact@pdc-line-pharma.com
www.pdc-line-pharma.com
www.linkedin.com/company/pdc-line-pharma
PDC*line Pharma (@pdc_line) / X

CONTACT
Mr Eric Halioua, President & CEO
+32 474 05 78 66
e.halioua@pdc-line-pharma.com

COMPANY BACKGROUND

PDC*line Pharma is a clinical-stage biotech company that develops an innovative class of cancer vaccine, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €61M in equity and non-dilutive funding.

ADDED VALUE

• A professional antigen-presenting cell line, much more potent than conventional dendritic cells in priming and expanding antitumor-specific cytotoxic CD8+ T-cells (conventional tumor antigens and neoantigens).
• While allogeneic, PDC*line can be injected several times to boost the immune response.
• Easily produced on a large scale, with a fully mastered and simple manufacturing process.
• Easy to use: after thawing, the same off-the-shelf product is used to treat the whole target population with a cancer type expressing the target antigens.
• Very versatile: tumor antigens can be provided by peptide loading, mRNA transfection or retrovirus transduction of PDC*line. Moreover, within a few weeks new candidates can be validated for new cancer indications, with ex vivo testing using human Peripheral Blood Mononuclear Cells (PBMC).
• Synergizes with anti-PD-1 to activate antitumor CD8 T-cells.

MAIN REFERENCES

In March 2019, PDC*line Pharma granted the LG Chem Life Sciences company an exclusive license in South Korea and an exclusive option in other Asian countries for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia.

CERTIFICATIONS

GMP manufacturing unit in house.

Q1 SCIENTIFIC

Rue de Waremme, 119,
B - 4530 Villers-le-Bouillet
info.cbe@cambrex.com
www.q1scientific.com/belgium
www.linkedin.com/company/q1-scientific-belgium/
https://twitter.com/Q1Scientific

CONTACT
Ms Cécile Jacoby, General Manager
+32 477 61 34 25
cecile.jacoby@cambrex.com

COMPANY BACKGROUND

If you are looking for a secure, reliable and cost-effective way to store your pharmaceutical and medical device products under any ICH or custom temperature and humidity condition, you need Q1 Scientific, the leader in outsourced stability storage. With walk-in rooms and reach-in cabinets that are fully validated and monitored 24/7, Q1 Scientific can store your samples at any ICH or custom temperature and humidity condition, from -80°C ultra-low freezer storage to over 50°C.

ADDED VALUE

Maximising opportunities, minimising risk and reducing stability storage costs. Operating from facilities in Belgium and Ireland, Q1 Scientific helps improve the speed of new drugs and medical devices reaching the marketplace along with saving companies the expense of building and monitoring their own storage chambers.Q1 Scientific is not just a storage provider, it is your trusted partner for stability storage excellence.

RANGE OF PRODUCTS

Outsource your pharmaceutical and medical device stability storage for long-term, intermediate and accelerated stability trials across a range of conditions:
All ICH stability storage (from 25°C to 40°C) /Refrigerated, freezer and ultra-low freezer storage (from 5°C to - 80°C) / R&D custom stability storage conditions / Freeze/thaw thermal cycling / Photostability Studies / Disaster Recovery Services.

MAIN REFERENCES

“Q1 Scientific offers direct contact with qualified people who know what is required. This ensures the project is straightforward from start to finish. It was a pleasure to deal with the Q1 staff who carried out their duties in a friendly and efficient manner.” Technical Manager, Healthcare Manufacturer.

CERTIFICATIONS

At Q1 Scientific we maintain an extensive Quality Management System to control and manage every aspect of our sample storage and management service. All our facilities work to GMP and Good Distribution Practices (GDP). In 2022, Q1 Scientific became ISO 9001 certified.

BELGIUM-WALLONIA@BIO-EUROPE SPRING 2024

QUALIBLOOD

Rue du séminaire, 20a
B - 5000 Namur
contact@qualiblood.eu
www.qualiblood.eu
www.linkedin.com/company/qualiblood/

CONTACT
Ms Julie Winand, CBDO
+32 472 96 89 29
julie.winand@qualiblood.eu

COMPANY BACKGROUND

QUALIblood provides the biotech and pharma industries, hospitals and universities with high tech analytical services for biomarker investigations from preclinical up to post market studies.
We design customized solutions, define analytical protocols, develop and validate specific analytical methods for biomarker evaluation.
Each project is managed by a complementary team in a GCLP/GLP and ISO17025 compliant environment.

ADDED VALUE

We offer our experimented support in biomarkers analyses by providing:
• A portfolio of more than 600 biomarkers in the field of hemostasis, woman health, infectious diseases, neurology, immune-oncology, ...
• Assistance in protocol definition to determine the testing strategy in line with the regulatory requirement and the scientific literature.
• Advice on (pre)analytical issues according to laboratory standards.
• Biobank service via our partnership with a notified biobank (NAB-X).

RANGE OF PRODUCTS

We offer services in bioanalysis in the field of health product development to evaluate their safety and efficacy. Our portfolio gathers standard analyses of blood derivatives and tailor made services/analyses bases on customer needs.

SEQALIS

Avenue Georges Lemaître, 25
B – 6041 Gosselies
info@seqalis.com
www.seqalis.com
www.linkedin.com/company/seqalis/?originalSubdomain=be

CONTACT
Mr Jean-Luc Henrioul, Chief Operating Officer - COO
+32 492 11 32 99
jl.henrioul@seqalis.com

COMPANY BACKGROUND

SEQALIS offers top-notch analytical services in anatomo-pathology and IHC, Cytogenomics and Molecular Biology (Next Gen Sequencing, PCR, ...) to the players of the pharma sector for discovery, pre-clinical and early clinical activities.

ADDED VALUE

Beside second to none quality analytical services, we offer medico scientific advice and results interpretation by in-house medical doctors, clinical oncologists, pathologists, geneticists, ...
Our proprietary qTCR Seq analytical platform is a truly quantitative un-biased platform for immuno-monitoring and biomarkers discovery (predictive, companion and of toxicity).

RANGE OF PRODUCTS

Our enabling analytical platforms provide second to none services to the actors within the fields of immuno-oncology, ATMPs and microbiology/microbiome.

MAIN REFERENCES

We have on-going successful collaboration with pioneering and leading biotechs in their respective domains of expertise especially in immuno-oncology.

CERTIFICATIONS

Seqalis complies with the ISO 9001 certification and works alongside the ISO 15189 certification implemented within the mother company, the Institute of Pathology and Genetics, IPG.

BELGIUM-WALLONIA@BIO-EUROPE SPRING 2024

SPECTRALYS BIOTECH

Rue Auguste Piccard, 48
B - 6041 Gosselies
info@spectralysbiotech.com
www.spectralysbiotech.com
www.linkedin.com/company/spectralys-biotech

CONTACT
Ms Allison Derenne, General Manager
+32 497 05 67 08
allison.derenne@spectralysbiotech.com

COMPANY BACKGROUND

Spectralys Biotech offers analytical services for structural characterization dedicated to biopharmaceutical products leveraging our sharp expertise in infrared spectroscopy (FTIR), circular dichroism (CD) and hydrogen-deuterium exchange monitored by mass spectrometry (HDX-MS). We originated from an academic laboratory at Université libre de Bruxelles. There, researchers are for example working on structure of membrane and amyloid proteins.

ADDED VALUE

FTIR spectra provide robust fingerprint of biological samples and account not only for the chemical nature of molecules but also for their conformation. They are particularly sensitive to protein and nucleic acid higher-order structure, just like CD spectra. HDX-MS is a powerful biophysical tool to provide information regarding protein conformation, dynamics and binding, at the peptide level resolution. No crystallization is required.

RANGE OF PRODUCTS

FTIR and CD spectroscopy allow the prediction of protein secondary structure and the study of DNA/RNA higher-order structure. FTIR spectroscopy has many other applications including glycosylation assessment, batch-to-batch consistency check, stability/stress studies and comparison of the lipid to protein/RNA ratio. The three main applications for HDX-MS are epitope mapping, study of protein-ligand interaction and evaluation of conformational changes.

MAIN REFERENCES

The company has been incorporated in October 2018. From then, we have already carried out more than 100 projects with approximately 42 companies of all sizes (from small biotech to big pharma). Alzinova, Xenikos, Curavac and Biofidus have attested the quality of our expertise and services. We do also participate to many publications (around two each year) in collaboration with Belgian universities.

SYNABS

Rue Auguste Piccard, 48
B - 6041 Charleroi
info@synabs.be
www.synabs.be
www.linkedin.com/company/synabs/?viewAsMember=true

CONTACT
Mr Julien Isoard, CEO
+32 483 74 39 04
isoardj@synabs.be

COMPANY BACKGROUND

SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line IR983. SYnAbs' vision is to fill the gap on the marketplace for innovative monoclonal antibodies against poor immunogenic compounds and complex homologous antigens. We provide complete antibody generation service from antigen synthesis to gram-scale manufacturing as well as antibody engineering.

ADDED VALUE

In order to address the challenge of raising innovative monoclonals against haptens and membrane proteins, SYnAbs has developed a set of technologies, combining:
• Innovative antigen design via proprietary assets such as SYnDNA vector, conformational SYnPEP peptides, SYnCell syngeneic cell lines and in-house adjuvant.
• Multi-species immunization in proprietary rat-LOU species, wild type and ATX-Gx transgenic mouse platform.
• Strategic immunization to break immune tolerance and trigger specific epitopes.
• Selection and isolation of rare B cell populations.

RANGE OF PRODUCTS

Therapeutic anti-hCCR8 monoclonal antibody / Therapeutic anti-hMMP9 monoclonal antibody / Therapeutic anti-hIL1RAP monoclonal antibody / Therapeutic anti-hIL1B monoclonal antibody / Diagnostic monoclonals specific to hemoglobin mutations HbA, HbC, HbE, HbS, and pan-Hb to detect sickle cell disease / Anti-Drug Antibodies (steroids, small peptides, antibody drug conjugates, idiotypes...) / Surrogate Antibodies to various complex epitopes.

MAIN REFERENCES

Domain Therapeutics, Coris Bioconcept, Volition, MedImmune, Neurogenic, Werfen, Horiba.

CERTIFICATIONS

ISO 9001.

SYNGULON

Rue du Bois Saint-Jean 15/1
B - 4102 Seraing
contact@syngulon.com
www.syngulon.com
www.linkedin.com/company/syngulon

CONTACT
Mr Guy Hélin, CEO
+32 475 47 07 08
ghelin@syngulon.com

COMPANY BACKGROUND

Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins solving 3 problems:
- Antibiotic-free technologies for production in a fermentation process.
- Prevention of contamination targeting bacteria having a negative effect on the production process.
- Alternative or complement to antibiotics in the context of AntiMicrobial Resistance AMR and microbiome.

MAIN REFERENCES

Licensing agreement with Enzymicals AG.
Integrated offer of TWB (Toulouse White Biotechnology).
MOU with EPPEN.

CERTIFICATIONS

Solar Impulse Efficient Solution label.

WHITE RAVEN

Rue Adonis Descamps, 71
B - 7021 Mons
hello@whiteraven.bio
www.whiteraven.bio
www.linkedin.com/company/whiteravenbio

CONTACT
Mr Jeroen Mangelschots,
Business Development Executive
+32 470 83 43 93
jeroen@whiteraven.bio

COMPANY BACKGROUND

White Raven, located in Legiapark in Belgium, is a flexible CDMO who specializes in GMP Formulation and Aseptic Filling of Injectable Drugs for small to medium sized batches.
Using state-of-the art gloveless robotic equipment we significantly reduce the chance for human errors and cross contamination.We tailor our services and products to align with the unique requirements of each client while respecting standard manufacturing procedures.

ADDED VALUE

We focus on developing and emerging biopharma companies that experience bottlenecks with the current Fill & Finish service providers in terms of long lead times, lack of flexibility and transparency, and high cost. We tackle those issues by using a fully single-use setup that reduces cross-contaminations, and a fully gloveless robotic filling process that eliminates human intervention and errors.
Through this innovative manufacturing approach, we allow our clients to focus on their products, while we deliver their batches in only 4 months!

RANGE OF PRODUCTS

Aseptic Formulation and Filling Solutions:
- Sterile filtration.
- Batch size from ~100 up to ~20,000 units.
- Containers: vials, syringes, and cartridges.

Additional Services:
- Formulation development.
- Analytical testing.
- Analytical Method Development and Validation.
- Secondary Packaging.
- Double blindness Masking.
- Terminal sterilization.
- Retention samples.
- Stability testing.
- Specific conditions storage (temp, humidity, etc...).
- Shipping.

Wallonia.be
EXPORT
INVESTMENT

WALLONIA EXPORT & INVESTMENT AGENCY

Place Sainctelette 2
B - 1080 BRUSSELS
BELGIUM
Phone:+32 2 421 82 11

info@awex.be
www.awex-export.be

Avenue des Dessus de Lives 6
B - 5101 NAMUR
BELGIUM
Phone: +32 81 33 28 50

welcome@investinwallonia.be
www.investinwallonia.be